Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer

  • Authors:
    • Tsukasa Hotta
    • Katsunari Takifuji
    • Kazuo Arii
    • Shozo Yokoyama
    • Kenji Matsuda
    • Takashi Higashiguchi
    • Toshiji Tominaga
    • Yoshimasa Oku
    • Hiroki Yamaue
  • View Affiliations

  • Published online on: August 1, 2005     https://doi.org/10.3892/or.14.2.433
  • Pages: 433-439
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

l-leucovorin (LV)/5-fluorouracil (5FU) may play an important role, as an adjuvant chemotherapy, in improving the survival of patients with stage III colorectal cancer. However, severe toxicity of the chemotherapeutic agent could be fatal. Adverse effects, including bone marrow suppression, liver damage, renal damage, and glucose tolerance, were evaluated daily during 3 courses of l-LV/5FU-modified RPMI regimen adjuvant chemotherapy for 22 patients with stage III colorectal cancer. Decrease in the serum levels of neutrophils and platelets occurred in the 1st course, which became more obvious after three or four administrations of l-LV/5FU in the 1st course. Furthermore, serum levels of leukocytes, neutrophils, and platelets on the re-start day of this chemotherapy after 2-week intervals were lower than those on the start day of this chemotherapy. In the evaluation of liver damage, renal damage, and glucose tolerance; serum alanine aminotransferase level in the 2nd course, serum total bilirubin (T.Bil) level in the 1st course, and serum creatinine level in the 1st course deteriorated during the course. T.Bil levels on the re-start day of this chemotherapy after 2-week intervals were especially high compared to that on the start day. The more courses of this chemotherapy we perform, the more attention we must pay to bone marrow suppression and hyperbilirubinemia. Thus, we clarified the attentive point of side effect of l-LV/5FU adjuvant chemotherapy for colorectal cancer.

Related Articles

Journal Cover

August 2005
Volume 14 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y and Yamaue H: Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Oncol Rep 14: 433-439, 2005
APA
Hotta, T., Takifuji, K., Arii, K., Yokoyama, S., Matsuda, K., Higashiguchi, T. ... Yamaue, H. (2005). Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Oncology Reports, 14, 433-439. https://doi.org/10.3892/or.14.2.433
MLA
Hotta, T., Takifuji, K., Arii, K., Yokoyama, S., Matsuda, K., Higashiguchi, T., Tominaga, T., Oku, Y., Yamaue, H."Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer". Oncology Reports 14.2 (2005): 433-439.
Chicago
Hotta, T., Takifuji, K., Arii, K., Yokoyama, S., Matsuda, K., Higashiguchi, T., Tominaga, T., Oku, Y., Yamaue, H."Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer". Oncology Reports 14, no. 2 (2005): 433-439. https://doi.org/10.3892/or.14.2.433